Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 2/20 | 0.38 |
| ▸ | LGMN | Q99538 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.36 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4751849 | 0.84 | MAPT (0.50) | MAPTGAASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL14320645 | 0.81 | MAPT (0.56) | MAPTGAASMN1; SMN2BRAFLGMN | |
| SCHEMBL26241577 | 0.78 | MAPT (0.54) | MAPTGAASMN1; SMN2BRAFLGMN | |
| SCHEMBL31556702 | 0.78 | MGLL (0.43) | MAPTGAASMN1; SMN2P2RY12ALDH1A1 | |
| SCHEMBL24630249 | 0.76 | MAPT (0.61) | MAPTGAASMN1; SMN2BRAFLGMN | |
| SCHEMBL13455200 | 0.76 | MAPT (0.61) | MAPTGAASMN1; SMN2BRAFLGMN | |
| SCHEMBL188672 | 0.76 | MAPT (0.61) | MAPTGAASMN1; SMN2BRAFLGMN | |
| SCHEMBL29769230 | 0.76 | MAPT (0.61) | MAPTGAASMN1; SMN2BRAFLGMN | |
| SCHEMBL3542981 | 0.75 | MAPT (0.47) | MAPTGAASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL1476490 | 0.74 | MAPT (0.49) | MAPTGAASMN1; SMN2BRAFLGMN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570614-B2 | Phenyl amino pyrimidine compounds and uses thereof | GLAXOSMITH KLINE LLC (US) | 2026-03-10 | — | — | US | disclosed |
| US-20220388967-A1 | Phenyl Amino Pyrimidine Compounds and Uses Thereof | SIERRA ONCOLOGY, INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-20210309615-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE LLC | 2021-10-07 | — | — | US | disclosed |
| CN-104030990-B | Phenyl amino pyrimidine compounds and application thereof | YM生物科学澳大利亚私人有限公司 | 2017-01-04 | — | — | CN | disclosed |
| EP-3023422-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | YM BioSciences Australia Pty Ltd (AU) | 2016-05-25 | — | — | EP | disclosed |
| US-9238628-B2 | Phenyl amino pyrimidine compounds and uses thereof | YM Biosicences Australia PTY LTD (US) | 2016-01-19 | — | — | US | disclosed |
| US-9233934-B2 | Phenyl amino pyrimidine compounds and uses thereof | YM BIOSCIENCES AUSTRALIA PTY LTD (US) | 2016-01-12 | — | — | US | disclosed |
| EP-2152701-B1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | YM BIOSCIENCES AUSTRALIA PTY (AU) | 2015-11-11 | — | — | EP | disclosed |
| US-20140011803-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE LLC | 2014-01-09 | — | — | US | disclosed |
| US-20140005180-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE LLC | 2014-01-02 | — | — | US | disclosed |
| US-8486941-B2 | Phenyl amino pyrimidine compounds and uses thereof | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2013-07-16 | — | — | US | disclosed |
| US-8486941-B2 | Phenyl amino pyrimidine compounds and uses thereof | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2013-07-16 | — | — | US | disclosed |
| US-20100197671-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE LLC | 2010-08-05 | — | — | US | disclosed |
| US-20100197671-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE LLC | 2010-08-05 | — | — | US | disclosed |
| EP-2152701-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | Cytopia Research Pty Ltd (AU) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008109943-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | CYTOPIA RESEARCH PTY LTD (AU) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197671-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | JAK2, JAK1, JAK3 | MAPT 3686/4885GAA 3092/4885SMN1; SMN2 4595/4885 |
| US-12570614-B2 | Phenyl amino pyrimidine compounds and uses thereof | JAK1, JAK2, JAK3 | MAPT 4698/4885GAA 4694/4885SMN1; SMN2 4092/4885 |
| US-20140011803-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | JAK2, JAK1, JAK3 | MAPT 3686/4885GAA 3092/4885SMN1; SMN2 4595/4885 |
| US-20210309615-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | JAK2, JAK1, JAK3 | MAPT 3686/4885GAA 3092/4885SMN1; SMN2 4595/4885 |
| US-20220388967-A1 | Phenyl Amino Pyrimidine Compounds and Uses Thereof | JAK2, JAK1, JAK3 | MAPT 3686/4885GAA 3092/4885SMN1; SMN2 4595/4885 |
| US-20140005180-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | JAK2, JAK1, JAK3 | MAPT 3686/4885GAA 3092/4885SMN1; SMN2 4595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.